Appendix

Figure S1: Assumed causal model in DAG with named covariates.




Table S1: Probability of being uncensored in the primary study population.

	Status	N	Min.	1st Qu.	Median	Mean	3rd Qu.	Max.
Ampicillin	uncensored	32006	0.09%	0.97%	1.77%	2.24%	2.91%	18.66%
	censored	3077087	0.00%	0.15%	0.84%	1.02%	1.28%	20.35%
Amoxicillin/	uncensored	18797	0.05%	0.56%	1.13%	1.37%	1.86%	11.10%
clavulanic acid	censored	3090296	0.00%	0.08%	0.48%	0.60%	0.71%	11.13%
Piperacillin/	uncensored	37295	0.09%	1.12%	2.13%	2.71%	3.61%	23.87%
Tazobactam	censored	3071798	0.00%	0.17%	0.94%	1.18%	1.43%	24.99%
Gentamicin	uncensored	41317	0.11%	1.24%	2.36%	2.95%	3.86%	23.62%
	censored	3067776	0.00%	0.19%	1.06%	1.31%	1.59%	25.41%

Ciprofloxacin	uncensored	37516	0.10%	1.12%	2.14%	2.65%	3.47%	21.95%
Ciprofloxacin	censored	3071577	0.00%	0.18%	0.96%	1.19%	1.45%	23.52%

Table S2: First Stage Regression Coefficients for IV Estimation

	Ampicillin	Amoxicillin/clavulanic acid	Piperacillin/tazobactam	Gentamicin
	Beta(s.e.)	Beta(s.e.)(1)	Beta(s.e.)(1)	Beta(s.e.)(1)
IV	0.23***	0.22***	0.23***	0.23***
t-statistics:	29.5	21.5	31.4	32.8

^{***} p-value < 0.001, ** -val < 0.01, * p-value 0.05

Table S3: IV-Estimated Risk Differences of AMR Rates: A Comparison between Exposure to Penicillins and Other Antibiotics Across Varying Time Points Post-Exposure, Limited to Amoxicillin, Amoxicillin without Other Penicillins, and Amoxicillin with Other Penicillins

Penicillin	AMR Antibiotic	Follow up length	Number of AMR Tests	RD IV (1)(2)	2.50%	97.50%	NNH
Amoxicillin/clavu	Amoxicillin/clavulanic acid	Up to: 90 days	6455	52.7%	31.8%	79.8%	1.9
		Up to: 180 days	10362	37.4%	22.0%	53.1%	2.7
lanic acid		Up to: 270 days	13226	28.5%	15.4%	41.1%	3.5
		Up to: 365 days	15356	25.5%	14.5%	37.1%	3.9

⁽¹⁾ Adjusted for sex, age, ses, social sector, comorbidities (ckd, cardio-vascular disease, diabetes mellitus, hypertension a immunosuppression), calendar time, previous urine culture tests count and previous antibiotic uses count

		Up to: 90 days	11238	29.8%	3.9%	56.1%	3.4
	Ampicillin	Up to: 180 days	17510	24.0%	3.9%	42.8%	4.2
		Up to: 270 days	21918	15.3%	-0.2%	31.9%	6.6
		Up to: 365 days	25253	14.8%	1.2%	28.7%	6.8
	-	Up to: 90 days	12655	4.6%	1.8%	7.2%	22.0
	Piperacillin/Tazobactam	Up to: 180 days	20111	3.4%	1.5%	5.3%	29.6
	Tiperaciiiii Tazobactaiii	Up to: 270 days	25611	1.8%	0.2%	3.5%	55.6
		Up to: 365 days	29865	1.3%	-0.1%	3.0%	74.6
	Gentamicin	Up to: 90 days	14356	1.5%	-10.8%	13.9%	65.8
		Up to: 180 days	22629	1.2%	-7.8%	9.8%	85.5
		Up to: 270 days	28524	0.1%	-6.3%	6.2%	714.3
		Up to: 365 days	33006	2.5%	-3.9%	8.3%	40.2
		Up to: 90 days	6459	48.3%	25.7%	72.3%	2.1
	Amoxicillin/clavulanic	Up to: 180 days	10540	32.2%	16.2%	46.3%	3.1
	acid	Up to: 270 days	13464	24.7%	13.7%	36.3%	4.1
Amoxicillin		Up to: 365 days	15684	22.5%	12.2%	32.4%	4.4
1 moziciiii		Up to: 90 days	11731	28.4%	9.8%	48.0%	3.5
	Ampicillin	Up to: 180 days	18396	22.4%	7.4%	39.2%	4.5
		Up to: 270 days	23049	17.6%	4.3%	31.0%	5.7
		Up to: 365 days	26585	18.1%	4.6%	29.8%	5.5
	_	-					

		Up to: 90 days	13106	2.8%	0.8%	4.7%	35.7
	Piperacillin/Tazobactam	Up to: 180 days	20960	2.4%	1.0%	3.8%	42.6
		Up to: 270 days	26710	1.5%	-0.1%	2.9%	67.6
		Up to: 365 days	31197	1.1%	-0.2%	2.4%	87.7
		Up to: 90 days	14889	-1.3%	-11.5%	7.2%	-76.9
	Gentamicin	Up to: 180 days	23591	-1.5%	-9.1%	6.1%	-67.6
	Gentamicin	Up to: 270 days	29772	-1.0%	-7.0%	4.7%	-100.0
		Up to: 365 days	34494	1.4%	-3.9%	6.1%	73.5
	Amoxicillin/clavulanic acid	Up to: 90 days	6705	39.2%	21.0%	57.9%	2.5
		Up to: 180 days	10998	26.0%	15.1%	38.4%	3.8
		Up to: 270 days	14103	20.7%	10.2%	30.0%	4.8
		Up to: 365 days	16468	18.4%	10.4%	26.6%	5.4
	Ampicillin	Up to: 90 days	12219	25.4%	6.6%	42.8%	3.9
Amoxicillin and		Up to: 180 days	19236	19.6%	6.8%	31.8%	5.1
Penicillin		Up to: 270 days	24161	14.9%	3.7%	26.5%	6.7
		Up to: 365 days	27943	15.0%	5.9%	24.7%	6.7
		Up to: 90 days	13612	2.1%	0.1%	3.6%	47.4
	Dinovacillin/Terrebeaters	Up to: 180 days	21871	1.8%	0.3%	3.0%	56.8
	Piperacillin/Tazobactam	Up to: 270 days	27953	1.1%	-0.2%	2.3%	92.6
		Up to: 365 days	32735	0.9%	-0.3%	2.1%	108.7

Gentamicin	Up to: 90 days	15489	-1.6%	-10.0%	6.1%	-62.5
	Up to: 180 days	24640	-2.0%	-8.8%	4.4%	-50.0
	Up to: 270 days	31179	-1.3%	-5.7%	3.7%	-75.8
	Up to: 365 days	36214	1.0%	-3.8%	5.5%	105.3

Table S4: IV-Estimated Risk Differences Across AMR Test Strata: Pairwise Comparisons of penicillin vs. Other Antibiotic Groups Within 180 Days Post-Exposure

			_	C		
AMR Antibiotic	Antibiotic Group Comparison	Number of AMR Tests	RD IV (1)(2)	2.5%	97.5%	NNH
	Cephalosporins	6420	12.0%	-8.5%	27.0%	8.4
	Macrolides	4532	13.2%	7.5%	19.1%	7.6
Amoxicillin/clavulanic acid	Tetracyclines	4918	15.3%	4.1%	24.8%	6.5
	Trimeth-sulfa	3695	24.5%	-3.5%	52.8%	4.1
	Fosfomycin Trometamol	3770	31.6%	7.1%	61.8%	3.2
	Nitrofurantoin	5181	18.4%	6.6%	32.0%	5.4
	Cephalosporins	11670	1.8%	-9.7%	16.7%	56.8
	Macrolides	8683	22.3%	16.7%	28.7%	4.5
Ampicillin	Tetracyclines	10003	8.1%	-2.2%	17.1%	12.4
	Trimeth-sulfa	7360	40.1%	6.6%	71.1%	2.5
	Fosfomycin Trometamol	7582	29.5%	4.6%	59.2%	3.4

	Nitrofurantoin	9506	21.5%	3.1%	39.8%	4.6
	Cephalosporins	12791	1.5%	0.0%	3.1%	67.1
	Macrolides	9390	1.3%	0.5%	2.0%	75.8
Piperacillin/Tazobactam	Tetracyclines	10564	2.6%	1.4%	3.7%	39.1
1	Trimeth-sulfa	7799	3.5%	-0.6%	8.1%	28.4
	Fosfomycin Trometamol	8033	1.8%	-3.9%	6.6%	55.6
	Nitrofurantoin	10627	2.0%	-0.3%	4.0%	49.0
	Cephalosporins	14591	-3.3%	-11.2%	3.1%	-30.6
	Macrolides	10714	-1.0%	-4.4%	2.1%	-102.0
Gentamicin	Tetracyclines	12291	-4.9%	-11.0%	1.9%	-20.4
Continue	Trimeth-sulfa	8954	-8.4%	-29.9%	8.0%	-12.0
	Fosfomycin Trometamol	9225	-9.3%	-30.7%	4.6%	-10.7
	Nitrofurantoin	11881	-4.2%	-12.5%	4.1%	-23.9

⁽¹⁾ Weighted with inverse probability of censoring (IPCW) weights

⁽²⁾ Adjusted for sex, age, ses, social sector, comorbidities (ckd, cardio-vascular disease, diabetes mellitus, hypertension and immunosuppression), calendar time, previous urine culture tests count and pervious antibiotic uses count

^{*} The negative NNH is interpreted as the absolute value of the NNH when switching the penicillins to be the comparator group.

Figure S2: Resistance Trends of Selected Antibiotics Against E. coli in Urine Cultures 2013-2022, MHS

